FDA approved GAMMAGARD LIQUID ERC for use, while EMA had already approved it as DEQSIGA. The company also benefited from market trends.
2 reports, 1 independent
Updated Jul 15
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approved GAMMAGARD LIQUID ERC for use, while EMA had already approved it as DEQSIGA. The company also benefited from market trends.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- FDA granted approvals for RASONQUE and WELTRUZA on November 4, 2026.
- Forbes reported on recent drug filings submitted to the FDA and the European Medicines Agency.
- FDA approved combination clearances for Elanco's Experior use on June 27, 2025.
- ADC Therapeutics received accelerated approval for its drug from the FDA.
- FDA approved a drug based on UVA research led by Xuemei Huang.
Coverage
Newest first; wire copies grouped- Insider MonkeyTakeda Pharmaceutical (TAK) Gets GAMMAGARD LIQUID ERC Approved by FDA Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the 13 Best Japanese Stocks to Buy According to Hedge Funds. On June 3
- Unknown outlet